• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines
【2h】

Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines

机译：乳腺癌细胞系中BCRA和逆向调制极光B激酶对低生存率对低生存率的关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Background New therapeutic drug for breast cancer (BRCA), especially triple negative BRCA (TNBC), is urgently needed. Even though 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) is an aurora kinase inhibitor, it also inhibits some cancer cells and human BRCA cells. However, the potential roles of reversine as a novel therapeutic agent for the treatment of BRCA remains unknown and must be further investigation. Thus, the relationship of reversine to aurora kinase in BCRA has not been reported. The relationship between AURKB and survival rate in BRCA has never been reported. Herein, we tested the roles of reversine on different BRCA cell line subtypes. We also investigated the relationship between AURKB and survival rate in BRCA as well as reversine to Aurora kinase expression in BCRA cell lines, including TNBC subtype, 4T1, MDA-MB-231, and luminal subtype MCF-7. Methods Cell viability and apoptosis were detected using Cell Counting Kit-8 and flow cytometry analysis, respectively. Apoptotic and tumor-related proteins were tested using Western blot analysis. Important microRNAs that regulate BRCA were analyzed using RT-PCR. UALCAN public databases were used to analyze the targeted gene profiles, and the PROGgeneV2 database was used to study the prognostic implications of genes. Results Reversine inhibits cell proliferation and induces cell apoptosis by modulating caspase-3 and bax/bcl-2 among the three cell lines. Data from the UALCAN public database show that BRCA tissues expressed high gene levels of AURKB, TIMP1, MMP9, and TGFB1 compared with the normal tissue. Among the over-expressed genes in BRCA, AURKB ranks 9th in TNBC, 49th in luminal subtype, and 48th in HER2 subtype. High AURKB level in BRCA is highly related to the low survival rate in patients displayed in 18 databases searched via PROGgeneV2. The protein levels of aurora B kinase (Aurora B), which is encoded by AURKB gene, are highly suppressed by reversine in the three cell lines. The tumor-related proteins TGF-β1, TIMP1, and MMP9 are partially suppressed by reversine but with different sensitivity in the three cell lines. The reversine-affected microRNAs, such as miR129-5p, miR-199a-3p, and miR-3960, in MDA-MB-231 cell line might be the research targets in TNBC regulation. Conclusions In BRCA, the level of AURKB are over-expressed and is related to low survival rate. Reversine contributes to anti-growth effect in BRCA cell lines, especially for TNBC, by modulating the aurora B. However, the invasiveness, metastasis, and anti-tumor effects of reversine in vivo and in vitro must be further investigated.
机译：摘要背景技术乳腺癌（BRCA）的新治疗药，尤其是三重阴性BRCA（TNBC）。尽管2-（4-麦克洛尼硅氧氨基）-6-环己酰胺（逆转录）是一种极光激酶抑制剂，它也抑制了一些癌细胞和人BRCA细胞。然而，逆转录作为新型治疗BRCA治疗剂的潜在作用仍然未知，必须进一步调查。因此，尚未报告逆转录到BCRA中的逆脉激酶的关系。从未报道过AURKB与BRCA生存率之间的关系。在此，我们测试了逆转录对不同BRCA细胞系亚型的作用。我们还研究了BCRA细胞系中AurkB和BRCA生存率与生存率的关系，包括TNBC亚型，4T1，MDA-MB-231和Luminal亚型MCF-7的Aurora激酶表达。方法使用细胞计数试剂盒-8和流式细胞术分析检测细胞活力和细胞凋亡。使用Western印迹分析测试凋亡和肿瘤相关蛋白质。使用RT-PCR分析调节BRCA的重要MicroRNA。 UALCAN公共数据库用于分析目标基因型材，并用于研究基因的预后含义。结果通过调节三种细胞系中的Caspase-3和Bax / Bcl-2调节Caspase-3和Bax / Bcl-2来抑制细胞增殖并诱导细胞凋亡。来自Ualcan公共数据库的数据表明，与正常组织相比，BRCA组织表达了AurkB，TIMP1，MMP9和TGFB1的高基因水平。在BRCA的过表达基因中，Aurkb在TNBC中的第9位，腔内亚型49分，48位在HER2亚型中。 BRCA的高Aurkb水平与通过Proggenev2搜索的18个数据库中显示的患者的低生存率高。由Aurkb基因编码的极光B激酶（极光B）的蛋白质水平受三种细胞系中的逆转带高度抑制。肿瘤相关蛋白TGF-β1，TIMP1和MMP9被逆转器部分抑制，但在三个细胞系中具有不同的敏感性。 MDA-MB-231细胞系列MIR129-5P，MIR-199A-3P和MIR-3960的逆向受影响的MicroRNA可能是TNBC调节中的研究目标。结论在BRCA中，Aurkb的水平被过度表达，并且与低生存率有关。通过调节极光B，逆转导致BRCA细胞系中的抗生长效应，特别是对于TNBC。然而，必须进一步研究逆向和体内逆转的侵袭性，转移和抗肿瘤作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号